4497 results about "Side chain" patented technology

There is provided a composition for forming an EUV resist overlayer film that is used in an EUV lithography process, that does not intermix with the EUV resist, that blocks unfavorable exposure light for EUV exposure, for example, UV light and DUV light and selectively transmits EUV light alone, and that can be developed with a developer after exposure. A composition for forming an EUV resist overlayer film used in an EUV lithography process including a resin containing a naphthalene ring in a main chain or in a side chain and a solvent, in which the resin may include a hydroxy group, a carboxy group, a sulfo group, or a monovalent organic group having at least one of these groups as a hydrophilic group.

Problem to be Solved To provide an ophthalmic lens, which can be more safely worn, that is, to provide a material, which is transparent and has high oxygen permeability and a high hydrophilic property, and to provide a novel monomer to be a raw material thereof.

Solution A hydrophilic polysiloxane macromonomer contains polyoxyethylene as a hydrophilic side chains in a polysiloxane main chain, wherein transparency, oxygen permeability, and hydrophilic properties of the material are controlled by regulating the length of the polysiloxane main chain, the length of the hydrophilic polyoxyethylene side chains, and the number of the side chains.

The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula

for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.

This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers:

wherein

• R1, R2, R3, R4, R5 is independently H, halogen, C₁–C₄ alkyl, nitro, nitrile, C₁–C₄ alkoxy, halogenated C₁–C₄ alkyl, or halogenated C₁–C₄ alkoxy, wherein at least one of R1, R3, and R5 is nitro;
• R6 is H or protected or unprotected side chain of natural or unnatural α-amino acid; and
• B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases.

Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

The present invention relates, in part, to an oligonucleotide-core carrier comprising a carrier, and oligonucleotide groups covalently linked to the carrier. The oligonucleotide groups are capable of dissociably linking load molecules such as therapeutic agents. The oligonucleotide-core carrier may also comprise protective side chains, and targeting molecules.

The present invention provides a positively charged microporous membrane having a protein binding capacity about 25 mg/ml or greater comprising a hydrophilic porous substrate and a crosslinked coating that provides a fixed positive charge to the membrane. The present invention further provides a positively charged microporous membrane comprising a porous substrate and a crosslinked coating comprising pendant cationic groups. The membranes of the present invention find use in a variety of applications including ion-exchange chromatography, macromolecular transfer, as well as detection, filtration and purification of biomolecules such as proteins, nucleic acids, endotoxins, and the like.

Embodiments disclosed herein include a resin composition comprising two or more different kinds of thermosetting resins, wherein at least one of the two or more different kinds of the thermosetting resins is a multifunctional resin, and a core-shell particle having a core and a shell, wherein a composition of the core is different from a composition of the shell and the composition of the shell has a branched polymer structure comprising at least one main chain and at least one side chain, the main chain or the side chain containing at least one functional group that reacts with the thermosetting resin, a method of manufacturing the resin composition, and a composite comprising a reinforcing fiber and the resin composition.

The invention provides methods, systems and reagents for regulating pH-sensitive protein interaction by incorporating non-natural amino acids into the protein (e.g. an antibody, or its functional fragment, derivative, etc.). The invention also relates to specific uses in regulating pH-sensitive binding of antibodies to tumor site, by conferring enhanced tumor-specificity/selectivity. In that embodiment, the non-natural amino acids preferably have desirable side-chain pKa's, such that at below physiological pH (e.g. about pH 6.3-6.5) the non-natural amino acid confer enhanced binding to tumor antigens in acidic environments. Such non-natural amino acids can be incorporated by any suitable means, such as by utilizing a modified aminoacyl-tRNA synthetase to charge the nonstandard amino acid to a modified tRNA, which forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with natural tRNAs (e.g. the degenerate codon orthogonal system.

There is provided a positive type resin composition comprising (A) a resin component comprising within the principal chain a structural unit derived from a (meth)acrylate ester and incorporating an acid dissociable, dissolution inhibiting group containing a polycyclic group on an ester side chain section, for which the solubility in alkali increases under the action of acid, (B) an acid generator component which generates acid on exposure, and (C) an organic solvent, wherein the component (A) comprises both a structural unit derived from a methacrylate ester and a structural unit derived from an acrylate ester. According to such a resist composition, a resist pattern can be formed which displays little surface roughness and line edge roughness on etching, and also offers excellent resolution and a wide depth of focus range.

Film-forming compositions, as well as methods of making and using, wherein the compositions include an optional active agent, water, a surfactant, and a water-soluble or water-dispersible vinyl polymer comprising amine group-containing side-chains and a copolymerized hydrophobic monomer; wherein the amine equivalent weight of the polymer is at least about 300 grams polymer per equivalent of amine group.

A method of preparing negative-working, single-layer imageable elements improves their storage stability in a humid environment. The method includes enclosing the coated imageable elements in a water-impermeable sheet material that substantially inhibits the transfer of moisture to and from the imageable element. Such imageable elements include a radiation-sensitive composition that includes a radically polymerizable component, an initiator composition to provide radicals upon exposure to imaging radiation, a radiation absorbing compound, and a polymeric binder having poly(alkylene glycol) side chains.

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

The present invention relates to a process for making a bread product. The process includes the addition of a non-maltogenic exoamylase that hydrolyses starch to a starch medium, and the application of heat to the starch medium. The non-maltogenic exomylase cleaves one or more linear malto-oligosaccharides, predominantly consisting of from four to eight D-glucopyranosyl units, from non-reducing ends of amylopectin side chains. The non-maltogenic exoamylase has an endoamylase activity of less than 0.5 endoamylase units (EAU) per unit of exoamylase activity.

Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.

Compositions comprising a blend of two or more paper strengthening agents have improved stability compared with previously known paper strengthening agents. One component is a polymeric paper strengthening agent, preferably a wet strengthening agent. The other component is a stabilized polyacrylamide prepared by (1) reacting a first portion of glyoxal with a polyacrylamide having pendant amide groups to form a first reaction mixture comprising polyacrylamide; (2) adding an acid to the first reaction mixture to form a second reaction mixture having a reduced pH and comprising the polyacrylamide; and (3) adding a second portion of glyoxal to the second reaction mixture to form the stabilized polyacrylamide. If desired, an aldehyde scavenger can be included in one or more of step (1), step (2), step (3), or the stabilized polyacrylamide. Such compositions can be used to enhance the strength of paper, particularly the wet strength of paper.

Disclosed are compositions and methods for treating and modifying surfaces and for enhancing delivery of active agents to surfaces treated therewith, wherein the compositions comprise siloxane polymers functionalized with pendant moieties comprising two or more anionic groups, at least one anionic group being a carboxy group. When applied to a suitable surface, the present composition forms a substantially hydrophobic coating of the anionic functionalized siloxane polymer on the treated surface. These polymers effectively deposit on surfaces that have cationic sites, which are capable of forming bonds or linkages with the anionic groups of the polymer. The treated surface becomes hydrophobic due to the deposition of the anionic functionalized siloxane polymer, which then imparts a variety of end use benefits to that surface such as ease of cleaning, soil release, stain removal and prevention, conditioning, etc. The anionic functionalized siloxane polymer further acts as a carrier to deposit active agents onto the surface and to improve retention and efficacy of the active agents on the treated surface. The present compositions are useful in a variety of applications including oral care, hair and skin care, personal care, cosmetics, and fabric and hard surface cleaning and conditioning.

The invention relates to a modified copolyester slice or fiber and a relative preparation, wherein the slice is copolymerized from terephthalic acid, ethandiol, isophthalate esters of sulfonic acid sodium (or potassium), and fatty group dibasic alcohol (or relative alkylate) with side chain. And the preparation comprises that (1), mixing the ethandiol and the fatty group dibasic alcohol (or relative alkylate) into a mixed alcohol, adding catalyzer and stabilizer to esterify the terephthalic acid under 220-260Deg. C, (2), adding 1-9%mol isophthalate esters of sulfonic acid sodium (or potassium) relative to the terephthalic acid for polycondensation at 250-300Deg. C, (3), drying, fusing, spinning, and drawing to obtain the modified copolyester filament. The inventive product can dye anion paint and disperse paint into deep color at normal pressure, with better feeling, high contraction, hidden micro coiled property, simple preparation, low cost and batch production support.

The present invention provides polypeptide conjugates wherein a modifying group such as a water-soluble polymer, a therapeutic agent or a biomolecule is covalently linked to the polypeptide through a glycosyl linking group. In one embodiment, the polypeptide includes a glycosylation consensus sequence, wherein glycosylation occurs at an aromatic amino acid residue, such as the C-2 or the N-1 position of a tryptophan side chain. Exemplary polypeptides of the invention are those in which the glycosylation consensus sequence has been introduced into the amino acid sequence of the polypeptide by mutation. In another aspect the invention provides polypeptide conjugates wherein the modifying group is covalently linked to the polypeptide via a glycosyl mimetic linking group. Also provided are methods of making and using as well as pharmaceutical compositions containing the polypeptide conjugates of the invention. Further provided are methods of treating, ameliorating or preventing diseases in mammals by administering an amount of a polypeptide conjugate of the invention sufficient to achieve the desired response.

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Vitamin D compounds of formula (I) with a label attached to a spacer group in the 3 position are disclosed.In the above formula (I), X is an optionally substituted hydrocarbon group with a length of 0.8-4.2 nm, optionally containing the heteroatoms S, O, N or P; Y is H or OH; A is a label capable of binding with high affinity to a protein; R is an optionally substituted hydrocarbon side chain of a D vitamin or a D vitamin metabolite. Also disclosed is the preparation of formula (I).

The invention is based on the discovery that certain membranes, which include side chains or molecular “brushes” having, for example, tertiary amino functional groups, can be used as highly effective filters to capture viruses/virus particles from liquids without removal of proteins. New methods based on this discovery include removing viruses from liquids such as blood or plasma, removing viruses from pharmaceuticals, concentrating and/or purifying viruses, e.g., for use in gene therapy, and producing recombinant viruses in new bioreactors. The invention also includes new methods of therapy or adjunct therapy for viral infections, in which a patient's blood or plasma is filtered through the membranes to remove viruses to reduce the viral load. The invention also includes new bioreactors and viral filters containing the membranes.

Fumaric acid amides of the general formula (I)

wherein R¹ represents OR³ or a D- or L-amino acid radical —NH—CHR⁴—COOH bonded via an amide bond, wherein R³ is hydrogen, a straight-chained or branched, optionally substituted C_1-24 alkyl radical, a phenyl radical or C_6-10 aralkyl radical and R⁴ is a side chain of a natural or synthetic amino acid and R² represents a D- or L-amino acid radical —NH—CHR⁵—COOH bonded via an amide bond or a peptide radical comprising 2 to 100 amino acids bonded via an amide bond, wherein R⁵ is a side chain of a natural or synthetic amino acid, are used for preparing a drug (1) for the therapy of an autoimmune disease; (2) for use in transplantation medicine; (3) for the therapy of mitochondrial diseases; or (4) for the therapy of NF-kappaB mediated diseases.

One aspect of the present invention relates to a microsphere, comprising a hydrophilic polymer comprising a plurality of pendant anionic groups; a transition-metal, lanthanide or group 13-14 metal oxide, polyoxometalate or metal hydroxide or combination thereof; and a first radioisotope that emits a therapeutic β-particle. In certain embodiments, the microsphere further comprsies a second radioisotope that emits a diagnostic γ-ray; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In certain embodiments, the microsphere is composed of polymer impregnated with zirconia bound to ³²p as the source of the therapeutic β-emissions and ⁶⁷Ga as the source of the diagnostic γ-emissions. Another aspect of the present invention relates to the preparation of a microsphere impregnated with a radioisotope that emits therapeutic β-particles and a radioisotope that emits diagnostic β-emitting radioisotope and a γ-emitting radioistope; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In certain embodiments, said microspheres are administered to the patient through a catheter. In another embodiment, the microsphere is combined with the radioisotopes at the site of treatment.

A negative active material for a rechargeable lithium battery includes a core including an active material being capable of performing reversible electrochemical oxidation and reduction, and a coating layer on the surface of the core. The coating layer includes a reticular structure including —O-M-O— wherein M is selected Si, Ti, Zr, Al, or combinations thereof and an organic functional group linked to the M as a side chain. The organic functional group is selected from the group consisting of an alkyl group, a haloalkyl group, a substituted or unsubstituted aryl group, and combinations thereof. The negative active material for a rechargeable lithium battery according to the present invention can be applied along with an aqueous binder, and improve high capacity, good cycle-life, and particularly high capacity during charge and discharge at a high rate.

The present invention relates to a series of prodrugs of inhibitors of DP-IV with improved properties. The compounds can be used for the treatment of a number of human diseases, including impaired glucose tolerance and type II diabetes. The compounds of the invention are described by general formula (1); wherein R¹ is H or CN; R² is selected from CH₂R⁵, CH₂CH₂R⁵ and C(R³)(R⁴)—X²—(CH₂)_aR⁵; R³ and R⁴ are each independently selected from H and Me; R⁵ is selected from CON(R⁶)(R⁷), N(R⁸)C(=0)R⁹, N(R⁸)C(═S)R⁹, N(R⁸)SO₂R¹⁰ and N(R⁸)R¹⁰; R⁶ and R⁷ are each independently R¹¹(CH₂)_b or together they are —(CH₂)₂-Z-(CH₂)₂— or CH₂-o-C₆H₄-Z-CH₂—; R⁸ is H or Me; R⁹ is selected from R¹¹(CH₂)_b, R¹¹(CH₂)_bO and N(R⁶)(R⁷); R¹⁰ is R¹¹(CH₂)_b; R¹¹ is selected from H, alkyl, optionally substituted aryl, optionally substituted aroyl, optionally substituted arylsulphonyl and optionally substituted heteroaryl; R¹² is selected from H₂NCH(R¹³)CO, H₂NCH(R¹⁴)CONHCH(R¹⁵)CO, C(R¹⁶)═C(R¹⁷)COR¹⁸ and R¹⁹OCO; R¹³, R¹⁴ and R¹⁵ are selected from the side chains of the proteinaceous amino acids; R¹⁶ is selected from H, lower alkyl (C₁-C₆) and phenyl; R¹⁷ is selected from H and lower alkyl (C₁-C₆); R¹⁸ is selected from H, lower alkyl (C₁-C₆), OH, O-(lower alkyl (C₁-C₆)) and phenyl; R₁₉ is selected from lower alkyl (C₁-C₆), optionally substituted phenyl and R²⁰C(=0)OC(R²¹)(R²²); R²⁰, R²¹ and R²² are each independently selected from H and lower alkyl (C₁-C₆); Z is selected from a covalent bond, —(CH₂)_c—, —O—, —SO_d— and —N(R¹⁰)—; X¹ is S or CH₂; X² is O, S or CH₂; a is 1, 2 or 3; b is 0-3; c is 1 or 2; and d is 0, 1 or 2.

The present invention provide a planographic printing plate comprising a substrate having thereon a recording layer which comprises at least one of a polymer compound carrying on a side chain a functional group which generates sulfonic acid under influence of an acid, base or heating; and a photo acid-generating agent or acid-generating agent; thermal base-generating agent; or an infrared ray absorbing agent, and by this structure, a high sensitive positive type planographic printing plate which can be developed with water or requires no developing is provided.

A biodegradable antithrombotic conjugate having heparin and other anti-thrombotic moieties are introduced as side chains to the polymer backbone modified by click chemistry. Various bioabsorbable monomers and dimers such as valerolactone may be used in the monomer derivation, homo- and co-polymerization, and the conjugation with a biologically active molecule by click chemistry. A coating comprising a biocompatible and bioabsorbable polymer anti-thrombotic conjugate is applied to at least a portion of an implantable device to prevent or reduce the formation of thrombosis on the surface of the implantable device. A first or sub-layer of the coating is prepared by mixing a polymeric material and a biologically active agent with a solvent, thereby forming a homogeneous solution. A second or outer layer comprising the present anti-thrombotic conjugate may be applied over the inner drug-containing layers using, for example, a dip coating or spray coating process.

Vinyl carbonate endcapped polysiloxanes containing a fluorinated side chain are useful as biomaterials, especially hydrogel biomaterials, including contact lens materials.

A surgical tissue adhesive composition contains at least one 1,1-disubstituted electron-deficient olefin macromer. The adhesive composition of the invention has improved biocompatibility as well as controlled biodegradation characteristics and bioactivity. Adhesive co-monomer compositions contain at least one macromer with a pendant oligomer, polymer, or peptide chain as an acrylic ester of the reactive olefin. The polymers formed therefrom have a grafted brush-like nature. The composition is particularly useful for creating an adhesive bond at the junction of living tissue in surgical applications. The adhesive composition may further comprise co-monomer, co-macromer, cross-linker, or inter-penetrating polymer compounds containing peptide sequences that are bioactive or enzyme responsive. The peptide sequences are selected to promote tissue infiltration and healing in a particular biological tissue. The sequences may contain specific cell-adhesion, cell-signaling, and enzyme-cleavable domains. Furthermore, a degradable filler material may be included in the composition to create a reinforced composite. The filler preferably has a higher degradation rate than the polymer matrix, generating porosity upon degradation. The adhesive may further contain entrapped or incorporated drugs or biologics, including antibiotics or growth factors. The adhesive can be used to bind together the edges of living tissues during surgical procedures. The cured composition provides interfacial bonding and mechanical fixation while promoting tissue infiltration and replacement of the adhesive polymer.